Plasma exchange and early thyroidectomy in thyroid storm requiring extracorporeal membrane oxygenation

Huilin Koh¹, Manish Kaushik², Julian Kenrick Loh³ and Chiaw Ling Chng¹

¹Department of Endocrinology, ²Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore, and ³Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore

Correspondence
should be addressed
to H Koh

Email
huilin.koh@mohh.com.sg

Summary

Thyroid storm with multi-organ failure limits the use of conventional treatment. A 44-year-old male presented with thyroid storm and experienced cardiovascular collapse after beta-blocker administration, with resultant fulminant multi-organ failure requiring inotropic support, mechanical ventilation, extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy. Hepatic and renal failure precluded the use of conventional thyroid storm treatment and early plasma exchange was instituted. The patient underwent emergency thyroidectomy after four effective exchanges, with subsequent rapid reversal of multi-organ failure. The challenges of institution of plasma exchanges with ongoing ECMO support, dialysis and timing of thyroidectomy are discussed. This case highlights the important role of early therapeutic plasma exchange (TPE) as an effective salvage therapy for lowering circulating hormones and stabilization of patients in preparation for emergency thyroidectomy in patients with thyroid storm and fulminant multi-organ failure.

Learning points:

- Administration of beta-blockers in thyroid storm presenting with congestive cardiac failure may precipitate cardiovascular collapse due to inhibition of thyroid-induced hyperadrenergic compensation which maintains cardiac output.
- TPE can be an effective bridging therapy to emergency total thyroidectomy when conventional thyroid storm treatment is contraindicated.
- End-organ support using ECMO and CRRT can be combined with TPE effectively in the management of critically ill cases of thyroid storm.
- The effectiveness of plasma exchange in lowering thyroid hormones appears to wane after 44–48 h of therapy in this case, highlighting the importance early thyroidectomy.

Background

Thyroid storm with multi-organ failure confers very high mortality and management is challenging. When conventional treatment cannot be used, therapeutic plasma exchange (TPE) may be a salvage bridging therapy to emergency thyroidectomy. The combined use of TPE, CRRT and ECMO has not been described in the setting of thyroid storm management. This report described in detail the various treatment strategies employed in the management

of a critically ill case of thyroid storm, providing guidance to physicians managing such complex cases.

Case presentation

A 44-year-old male presented with 1 week of productive cough, sore throat, rhinorrhea and breathlessness. He also had symptoms of post-tussive vomiting and

diarrhea without abdominal pain. He was diagnosed with hyperthyroidism 4 months ago when he presented with loss of weight. Carbimazole 30mg daily was started by his primary physician. However, he defaulted treatment and follow-up after taking the medication for 6 weeks as his symptoms had improved. On physical examination, he was febrile at 38°C and was noted to be in atrial fibrillation (AF) with heart rate of 170bpm, blood pressure of 102/42mmHg, and hypoxic, with oxygen saturation of 92% on room air. He was initially alert and coherent with a Glasgow Coma Scale (GCS) of 15. He had signs of thyroid eye disease, with bilateral exophthalmos and lid retraction. There was no enlarged goiter or thyroid bruit. Cardiorespiratory examination revealed signs of congestive cardiac failure, with elevated jugular venous pressure, bilateral expiratory wheezing and bilateral pitting pedal edema up to mid shins.

Investigation

Initial laboratory investigations revealed severe hyperthyroidism, acute hepatitis, elevated inflammatory markers, cardiac enzyme and brain natriuretic peptide, as well as derangement in coagulation profile (Table 1). Electrocardiogram confirmed AF with rapid ventricular response of around 200bpm. Chest radiograph revealed an enlarged heart, right patchy consolidation and bilateral

pleural effusions, worse on the right. The presence of thermodynamism, cardiac and gastrointestinal manifestations of thyrotoxicosis contributed to a high Burch-Wartofsky score of 70. A diagnosis of thyroid storm was made.

Treatment

He was promptly treated with carbimazole 30mg, oral propranolol 20mg and Lugol's iodine (130mg/mL) ten drops (1h after carbimazole was administered). Intravenous digoxin 500µg was also initiated in view of the AF and cardiac failure. However, he suffered pulseless electrical activity (PEA) cardiovascular collapse during the infusion of digoxin, after propranolol was given. This was followed by three further PEA collapses, with return of spontaneous circulation each time after successful cardiopulmonary resuscitations. After a total of 40min of resuscitation and subsequent return of spontaneous circulation, he was intubated and placed on inotropic support using both adrenaline and noradrenaline infusions. However, he remained hypotensive despite maximum inotropic support. Venous-arterial extracorporeal membrane oxygenation (VA-ECMO) was initiated promptly and he was immediately transferred to our institution for further treatment.

Repeat laboratory investigations revealed worsening of his liver impairment and anuric acute kidney

Table 1 Laboratory investigations on presentation of thyroid storm.

Test	At initial presentation	Post PEA collapse on transfer for ECMO	Reference range
Urea	13.3	16.3	2.7–6.9 mmol/L
Creatinine	80	249	54–101 µmol/L
Sodium	133	142	136–146 mmol/L
Potassium	4.7	5.1	3.6–5.0 mmol/L
Bicarbonate		20.3	19.0–29.0 mmol/L
fT3	11.3	23.5	3.2–5.3 pmol/L
fT4	66	61.3	8.8–14.4 pmol/L
TSH	<0.01	0.266	0.65–3.7 mU/L
Bilirubin		64	7–32 µmol/L
Alkaline phosphatase	133	125	49–99 U/L
Alanine transaminase	668	4021	6–66 U/L
Aspartate transaminase	838	>7000	12–42 U/L
Gamma-glutamyl transferase	79		14–94 U/L
Procalcitonin	0.1	11.4	<0.5 µg/L
Lactate		8.2	0.5–2.2 mmol/L
Hemoglobin	13.7	10.6	14–18 g/dL
Total white count	6.7	21.1	4–10 × 10 ⁹ /L
Platelet	256	94	140–440 × 10 ⁹ /L
Prothrombin time	21.3	28.7	9.9–11.4 s
Partial thromboplastin time	30.8	41.2	25.7–32.9 s
Fibrinogen	3.1	0.59	1.8–4.8 g/L
Brain natriuretic peptide	619		0–100 pg/L
Troponin	60	85	<30 ng/L

injury (Table 1). A transthoracic echocardiography (TTE) revealed severely impaired left ventricular systolic function with visually estimated ejection fraction of 20–25%, dilatation of the right and left ventricles and cardiac congestion with pulmonary hypertension. Figure 1 summarizes the multi-organ failure and therapeutic measures initiated for this patient. A decision was made to institute early TPE until emergency total thyroidectomy could be performed. Intravenous hydrocortisone 100mg 6 hourly and cholestyramine 4g 8 hourly were also commenced as adjunctive therapy. As he was coagulopathic with disseminated intravascular coagulation (DIC), plasma exchange with 3L of fresh frozen plasma (FFP) was used for the first exchange via a left femoral vein double lumen dialysis catheter. (Infomed HF440 with Granopen plasmafilter, INFOMED SA, Geneva, Switzerland.) Concurrently, VA-ECMO was ongoing via right groin angio-access with simultaneous CRRT running off the ECMO circuit (Fig. 2).

After the first TPE, his inotropic support reduced to single noradrenaline infusion. Free triiodothyronine (FT3), free thyroxine (FT4) and thyroid stimulating hormone receptor antibodies (TRAbs) also improved markedly (Fig. 3 and Table 2).

He underwent a second TPE with 3L plasma exchange fluid consisting of 2L of 5% human albumin and 1L of FFP. Fourteen hours later, he was successfully weaned off inotropic support (Table 2). Two further plasma exchanges (3rd and 4th TPE exchange fluid: 2L of 5% Albumin and 1L of FFP) were performed prior to the emergency thyroidectomy (Fig. 3). In view of the need for continuous intravenous heparin with the

use of ECMO, a decision was made for ECMO explantation prior to thyroidectomy. He underwent successful ECMO explantation and subsequent total thyroidectomy 5 days after admission following four TPE.

Outcome and follow-up

Post-operatively, he remained off inotropic support and was started on levothyroxine replacement, titrated to 1.8µg/kg. He remained intubated for another 8 days due to persistent hyperammonemia secondary to ongoing liver and renal failure, contributing to continued obtunded mental state. He was eventually extubated on post-operative day (POD) 8 when his plasma ammonia level normalized. He subsequently underwent intensive rehabilitative therapy and was discharged 9 weeks after initial presentation.

Discussion

Thyroid storm is an uncommon but life-threatening endocrine condition characterized by extreme manifestations of thyrotoxicosis. In our institution, its prevalence among hospitalized patients with thyrotoxicosis was 1.05% (1). Hyperthyroidism induces a hyperadrenergic state and its effects on the cardiovascular system are complex. In prolonged uncontrolled hyperthyroidism, a combination of relative hypervolemia, reduced myocardial contractile reserve and tachyarrhythmia can result in cardiac failure. This 'high-output' heart failure usually occurs in young individuals with severe and long-standing hyperthyroidism in the absence of any underlying heart disease (2).

Figure 1
Schematic of multi-organ failure and therapeutic support required.

Figure 2
Schematic of simultaneous ECMO, CRRT and TPE.

Conventional thyroid storm treatment strategies simultaneously target against the synthesis, release and peripheral effects of thyroid hormones. High-dose propranolol is commonly employed to counter the hyperadrenergic state of thyrotoxicosis, with the added benefit of inhibiting peripheral conversion of T₄ to the more potent T₃. However, our patient experienced severe cardiovascular collapse after propranolol was administered. A systematic literature review by Abubakar *et al.* (3) found nine published reports of beta-blocker-induced cardiovascular collapse. Notably, low cardiac output heart failure with suppressed left ventricular ejection fraction (LVEF) was a common finding in these reports. While propranolol can counteract a high-output failure in the context of a preserved ejection fraction, it is potentially detrimental to administer it in 'low-output' cardiac failures with depressed ejection fraction, due to the negative inotropic effects of the beta-blockers in acute decompensated cardiac failure. Our patient had clinical evidence of heart failure on presentation and was subsequently found to have low ejection fraction of 20–25% on TTE. Although digoxin was initiated in our patient, he collapsed before the loading dose was completed. It is also noteworthy that cardiac glycosides are less effective in the hyperthyroid compared to euthyroid state due to its altered metabolism in hyperthyroidism (4). Thus, this case highlights the potential life-threatening adverse effect of using propranolol in patients with thyroid storm who present with heart failure.

TPE is generally employed in the management of thyroid storm when conventional treatment fails or cannot be used due to toxicity. Although rare, the use of TPE in thyroid storm is not new. It is now a category III

indication for thyroid storm (i.e. optimum role of apheresis therapy is not established; decision making should be individualized) according to the American Society for Apheresis (ASFA) 2013 guidelines on use of therapeutic apheresis (5). However, our case is the first reported use of TPE together with ECMO and CRRT in the treatment of thyroid storm. A search of the literature found that concurrent use of ECMO and TPE has been reported to be safe in adults and children in non-thyroid storm settings (6). The largest case series by Dyer *et al.*, which reviewed 76 cases which utilized both TPE and ECMO noted the most common indications for initiating TPE on top of ECMO were multi-system organ failure and transplant rejection (6). During TPE, a patient's plasma is extracted from its cellular components and replaced with a colloid such as albumin and/or plasma. Thyroid hormone-

Figure 3
Trend of thyroid hormones and thyrotropin receptor antibodies with plasma exchange.

Table 2 Serial FT3, FT4 and TRAb measures following four cycles of therapeutic plasma exchange.

Day	Time (h)	Hours from TPE (h)	FT3	FT4	TRAb
			Ref 3.2–5.3 (pmol/L)	Ref 8.8–14.4 (pmol/L)	Ref <1.5 (IU/L)
2	16:16	–5	23.5	61.3	
	21:41	0 (#1 start)	19.8	67.6	24.7
3	00:36	0 (#1 end)	18.2	58.2	12.4
	03:42	+3	16	61.7	
	08:13	+8	13.5	36.8	
	13:15	+13	11.3	59.6	
	17:57	–1	9.7	57.1	
	19:55	0 (#2 start)			
	21:15	0 (#2 end)			
4	00:02	+3	8.0	50.1	9.7
	06:25	+9	7.8	42.8	
	11:00	Weaned off ionotropic support			
	13:36	+16	5.8	40.8	
	15:20	ECMO explantation under general anesthesia			
	17:34	–2	6.0	34.9	
	19:00	0 (#3 start)			
	20:55	0 (#3 end)			
	22:59	+2	5.3	29.5	
5	04:50	0 (#4 start)			
	06:20	0 (#4 end)			
	07:32	+1	6.0	22.0	4.6
	14:00	+8	4.3	20	7.5
		Total thyroidectomy			

binding globulins (TBGs) with bound thyroid hormone is removed from circulation and the replacement colloid provides new binding sites for circulating free hormones, thereby reducing free hormone concentrations. TPE also removes circulating antibodies (TRAb), overall ameliorating thyrotoxicosis. However, clotting factors and immunoglobulins are also removed with TPE, increasing the risk of bleeding and infections. With the concomitant use of intravenous heparin to prevent clotting of the extracorporeal therapy circulations, the risk of bleeding increases manifold. Hence, we recommend that a portion of the TPE replacement fluid should consist of plasma (FFP), in order to replace some of these depleted clotting factors. However, this needs to be balanced with avoiding clotting of the ECMO and CRRT circuits; therefore, the remaining portion of TPE replacement fluid is made out of human albumin. The patient's blood-activated clotting time (ACT) was monitored and heparin infusion was titrated to a target ACT of 180–200s (institution ECMO protocol), and the patient was closely monitored for signs of bleeding. In addition, albumin was used together with FFP in the exchange colloid to reduce the volume of plasma required, as well as reduce the complications of FFP transfusion such as citrate toxicity and hypocalcemia.

This case also highlights the importance of the early use of TPE in thyroid storm. TPE was initiated within

24h of presentation when it was clear that hepatic and renal failure precluded the continued use of conventional thyroid storm treatment. Several authors (7, 8) as well as the ASFA guidelines (5) recommend to conduct TPE as early as possible in thyroid storm. Binimelis *et al.* described a 30-fold decrease in total thyroxine levels with plasma exchange as compared to conventional treatment, and this effect was proportional to the serum level of thyroxine (7). This suggests that TPE is more efficient if done early and also highlights the narrow effective therapeutic window of this treatment. Rapid clinical improvement was apparent in our patient after the first two plasma exchanges, although serum FT3 and FT4 remained high. We observed in our patient that the efficacy of plasma exchange dropped after the third TPE (44–48h after initiation of TPE).

The aim of TPE as a salvage bridging therapy was to render the patient fit enough for total thyroidectomy (definitive treatment of thyroid storm) under general anesthesia. Table 3 highlights the parameters we monitored to determine fitness for operation. There are differing opinions with regards to the timing of surgery after the last TPE. Ezer *et al.* reported safety with thyroidectomy within 24h after last exchange; unusual bleeding at the operation site only occurred in one out of eleven surgeries (9). Ozbey *et al.*, however, reported increased bleeding compared to

Table 3 Parameters monitored while awaiting total thyroidectomy.

Parameter	Target	Rationale
Thyroid hormone, fT3	Normal	Reduce the hyperadrenergic state caused by thyrotoxicosis Reduce general anesthetic (GA) risk
Blood pressure	Unsupported/minimal ionotropic support	Reduce surgical and GA risk
Cardiac ejection fraction	Wean off ECMO	IV heparin infusion with ECMO use increases peri-operative bleeding risk
Coagulopathy profile PT/PTT	Normal	Reduce peri-operative bleeding risk

the usual with thyroidectomy performed within 24h of TPE, in two out of four patients (10). They recommend delaying thyroidectomy to 48h after the last TPE and also to use FFP in the replacement fluid for the plasma exchange right before operation, to reduce the risk of bleeding. Our patient underwent thyroidectomy within 8h of TPE without any bleeding complications. Perioperatively, he received plasma, cryoprecipitate and platelet transfusion for correction of coagulopathy. We suggest that thyroidectomy is safe within 24h of TPE as long as any coagulopathy is promptly treated with blood products.

Conclusion

We highlight the first case of concurrent ECMO, TPE and CRRT in the treatment of thyroid storm. Early use of TPE was beneficial with rapid clinical improvement observed. The number of exchanges as well as timing of surgery with respect to last exchange needs to be considered on a case by case basis.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this case report.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Patient consent

Written informed consent has been obtained from the patient for publication of the submitted article and accompanying images.

Author contribution statement

H K was responsible for patient management, writing and editing the manuscript. M K, J K L were involved in patient management, editing and final

approval of the manuscript. C L C was involved in the patient management, overall supervision, editing and final approval of the manuscript.

References

- 1 Swee du S, Chng CL & Lim A. Clinical characteristics and outcome of thyroid storm: a case series and review of neuropsychiatric derangements in thyrotoxicosis. *Endocrine Practice* 2015 **21** 182–189. (<https://doi.org/10.4158/EP14023.0R>)
- 2 Klein I & Danzi S. Thyroid disease and the heart. *Circulation* 2007 **116** 1725–1735. (<https://doi.org/10.1161/CIRCULATIONAHA.106.678326>)
- 3 Abubakar H, Singh V, Arora A & Alsunaid S. Propranolol-induced circulatory collapse in a patient with thyroid crisis and underlying thyrocardiac disease: a word of caution. *Journal of Investigative Medicine High Impact Case Reports* 2017 **5** 232470961774790. (<https://doi.org/10.1177/2324709617747903>)
- 4 Huffman DH, Klaassen CD & Hartman CR. Digoxin in hyperthyroidism. *Clinical Pharmacology and Therapeutics* 1977 **22** 533–538. (<https://doi.org/10.1002/cpt1977225part1533>)
- 5 Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American Society for Apheresis. *Journal of Clinical Apheresis* 2010 **25** 83–177. (<https://doi.org/10.1002/jca.20240>)
- 6 Dyer M, Neal MD, Rollins-Raval MA & Raval JS. Simultaneous extracorporeal membrane oxygenation and therapeutic plasma exchange procedures are tolerable in both pediatric and adult patients. *Transfusion* 2014 **54** 1158–1165. (<https://doi.org/10.1111/trf.12418>)
- 7 Binimelis J, Bassas L, Marruecos L, Rodriguez J, Domingo MLP, Madoz P, Armengol S, Mangués MA & de Leiva A. Massive thyroxine intoxication: evaluation of plasma extraction. *Intensive Care Medicine* 1987 **13** 33–38. (<https://doi.org/10.1007/BF00263555>)
- 8 Muller C, Perrin P, Faller B, Richter S & Chantrel F. Role of plasma exchange in the thyroid storm. *Therapeutic Apheresis and Dialysis* 2011 **15** 522–531. (<https://doi.org/10.1111/j.1744-9987.2011.01003.x>)
- 9 Ezer A, Caliskan K, Parlakgumus A, Belli S, Kozanoglu I & Yildirim S. Preoperative therapeutic plasma exchange in patients with thyrotoxicosis. *Journal of Clinical Apheresis* 2009 **24** 111–114. (<https://doi.org/10.1002/jca.20200>)
- 10 Ozbey N, Kalayoglu-Besisik S, Gul N, Bozboru A, Sencer E & Molvalilar S. Therapeutic plasmapheresis in patients with severe hyperthyroidism in whom antithyroid drugs are contraindicated. *International Journal of Clinical Practice* 2004 **58** 554–558. (<https://doi.org/10.1111/j.1368-5031.2004.00140.x>)

Received in final form 28 May 2019

Accepted 2 July 2019